Medical Oncology Association of
Southern California
P.O. Box 161
Upland, CA 91785
Phone: (909) 985-9061
Fax: (909) 985-8581
email: moasc@moasc.org
|
|
|
MOASC would like to recognize and thank the following sponsors for their continued support of MOASC:







|
|
|
|
Posted October 4, 2005 |
|
SAVE THE DATE NOVEMBER 9, 2005
MOASC General Membership Meeting on November 9, 2005
at the Fairmont Hotel in Newport Beach, CA.
Speakers include:Joseph S. Bailes, M.D.Co-Chair, Government Relations Council,
ASCO "Washington Update"
Waiting for confirmation from second speaker.
The Reception is at 5:30pm and Dinner at 6:00pm.
The meeting will be held at the Fairmont Hotel 4500 MacArthur Blvd. Newport Beach, CA 92660
Phone: (949) 476-2001
Please R.S.V.P. with check or credit card * by November 2, 2005.
* Please note: A fully refundable registration fee of $10.00 will apply per R.S.V.P. Upon arrival at meeting this fee will be refunded.
If you should fail to attend, MOASC will cash check or charge credit card.
If you have would like to register or have any questions,
contact the MOASC office by email at: moasc@moasc.org or by telephone at (909) 985-9061.
|
|
Coding Changes Effect Billing Practices October 1, 2005
Be sure and review all current coding changes which effect billing guidleines and protocols October 1, 2005. ICD-9 Coding changes go to the boxes marked "effective Oct. 1, 2005" to find the new codes and the new invalid codes. http://www.cms.hhs.gov/medlearn/icd9code.asp
Some new changes to diagnosis codes relevant to oncology effective October 1, 2005 are:
V58.1 no longer valid
effective October 1, 2005 new codes:
V58.11* Encounter for antineoplastic chemotherapy
V58.12* Encounter for immunotherapy for neoplastic condition
276.5 is no longer valid
585 is no longer valid ........staging of kidney disease with the deletion of 585
effective October 1, 2005 new codes:
585.1 Chronic kidney disease, Stage I
585.2 Chronic kidney disease, Stage II (mild)
585.3 Chronic kidney disease, Stage III (moderate)
585.4 Chronic kidney disease, Stage IV (severe)
585.5 Chronic kidney disease, Stage V
585.6 End stage renal disease
|
|
Announcements
What's New (visit http://www.medicarenhic.com/whats_new/whats_new.shtml)
CA Updates (visit http://www.medicarenhic.com/cal_prov/updates.shtml)

The following updates (regarding claims, NPIs) have been posted on the CMS/Medicare website.
MM3627 - Requirements for Voided, Canceled, and Deleted Claims
http://www.cms.hhs.gov/medlearn/matters/mmarticles/2005/MM3627.pdf
SE0555 - Medicare’s Implementation of the National Provider Identifier (NPI): The Second in the Series of Special Edition Medlearn Matters Articles on NPI-Related Activities Revised: 9/28/2005 http://www.cms.hhs.gov/medlearn/matters/mmarticles/2005/SE0555.pdf
MM4044 - Redesigned Skilled Nursing Facility (SNF) Consolidated Billing (CB) Annual Update File and Discontinuation of the SNF Healthcare Common Procedure Coding System (HCPCS) Help File http://www.cms.hhs.gov/medlearn/matters/mmarticles/2005/MM4044.pdf

CMS Ends HIPAA Contingency Plan; Noncompliant Electronic Claims Will Be Rejected Effective Oct. 1
The Centers for Medicare & Medicaid Services (CMS) have announced that effective October 1, Medicare carriers will reject electronic claims that don’t meet the HIPAA transaction and code sets standards.
Although HIPAA transaction and code sets regulations took effect on October 16, 2003, CMS implemented a “contingency plan” that allowed more time for physicians and other health care providers to make the transition to HIPAA-compliant billing systems.
The decision to end the contingency plan was made because most physicians are now submitting compliant claims. In June 2005, 96 percent of physicians were in compliance, compared to only 80-85 percent in 2004.
|
|
MOASC Comments of the 2006 Fee Schedule
MOASC continues to work for for it's members by submitting comments to CMS regarding issues that will effect the oncology community. Read the MOASC 2006 Physician Fee Schedule Comments here>>

MOASC Comments on Drug CAP
Program
Although the CAP program has been stalled, MOASC submitted it's comments to CMS for official recognition of our position on the matter.
Read the MOASC CAP Comments here >>

HR 261
MOASC supports the efforts of collegial associations such as ASCO and COA in supporting Representative Ralph Hall (R-TX) and other Congresssional supporters to advance House Resolution 261, which urges CMS to continue the oncology demonstration project in 2006. We will continue to provide updates on timing and legislative action.
Contact the MOASC office for further details or ASCO's Cancer Policy & Clinical Affairs Department at 703-299-1050, or email publicpolicy@asco.org with any questions.

The Governor has acted on two of interest to MOASC
The Governor signed AB 929 Assemblymember Jenny Oropeza on radiologic technology and exposure. He also signed SB 650 by Senator Oritz on the Improving Access, Counseling, and Treatment for Californians with Prostate Cancer (IMPACT) Program.
SB 650 allocates $2.4 million to treat low-income, uninsured men suffering from prostate cancer. Approximately 366 patients will receive critical treatment under this program. In addition, the legislation requires 87 percent of the funding be spent on direct patient care. The Governor included a signing message, which I have attached.
If you have any questions, please do not hesitate to contact Kris Rosa at Noteware Government Relations, MOASC's state lobbist, Kris@frednoteware.com, she'll be happy to discuss with you.
|
|
Drug Recall
APP/Abraxis Oncology has informed us of a product recall for 5FU. Details are available at http://www.appdrugs.com/products1.cfm?page=ProdRecall
Your immediate attention to this matter is appreciated.
New Drug Indications
Recently, the United States Pharmacopeia-Drug Information (USP-DI)/Thomson Micromedex published its acceptance of new indications for trastuzumab (Herceptin), bevacizumab (Avastin), and cetuximab (Erbitux). The USP-DI monographs for these drugs have been revised to include the following off-label* uses:
Trastuzumab (Herceptin)
Accepted: Breast cancer, adjuvant, in combination with doxorubicin, cyclophosphamide, and paclitaxel for the treatment of HER-2 positive breast cancer. (Published 09/07/05)
Bevacizumab (Avastin)
Accepted: Non-squamous non small cell lung cancer, advanced/metastatic, first-line treatment, in combination with paclitaxel and carboplatin. (Published 09/06/05)
Cetuximab (Erbitux)
Accepted: Malignant tumor of head and neck, relapsed/refractory, as single agent and in combination with radiotherapy or platinum-based chemotherapy in the treatment of head and neck cancer. (Published 8/18/2005)

MOASC wishes to inform you that on August 10, 2005, the United States Pharmacopeia Drug Information (USPDI) listed Zometa (Zoledronic acid) Injection in its compendium for the treatment of drug-induced osteopenia, secondary to androgen-deprivation therapy in prostate cancer patients (prophylaxis). Zometa was approved by the United States Food and Drug Administration (FDA) for hypercalcemia of malignancy in August 2001 and it was subsequently approved in February 2002 for multiple myeloma and patients with documented bone metastases from solid tumors, in conjunction with standard cancer therapy.
|
|
|
|
|
|